The incidence of cardiovascular diseases is lower in women compared to men 1 that may be linked to a different vasoconstrictor sensitivity. 2 In the human forearm a greater vasoconstrictor response in men to exogenous noradrenaline has been demonstrated. [2] [3] [4] This has been explained by higher sensitivity of counteracting vasodilatory effects of vascular beta-adrenoceptors. 5 Forearm experiments cannot necessarily be extrapolated to the systemic circulation as clearly demonstrated by adrenoceptor studies in the cutaneous circulation. 6 We have therefore studied the systemic haemodynamic response to pharmacologic sympathetic stimulation in healthy male and female volunteers in two open-label studies using exogenous noradrenaline and tyramine in the absence and presence of nonspecific beta-adrenoceptor blockade by propranolol.
After approval by the Ethics Committee and written informed consent 20 female and 20 male healthy subjects aged 20-33 years received stepwise increasing intravenous doses of noradrenaline (0-160 ng/kg/min; Arterenol s , Aventis, Germany) and tyramine (0-20 mg/kg/min; Clinalfa, Läufelfingen, Switzerland). In the subsequent second study limb, 10 male and nine female volunteers who had participated in the first experiments received an i.v. infusion of propranolol (bolus 60 mg/kg, continuous infusion of 0.75 mg/kg/min) followed after 20 min by a co-infusion of increasing doses of noradrenaline (80 and 160 ng/kg/min, infusion period: 15 min/dose level) and tyramine (20 mg/kg/min over 15 min). Blood pressure, pulse rate and systolic time intervals 7 were measured at frequent intervals and noradrenaline plasma concentrations determined. In order to account for potential differences in cardiovascular reactivity from hormonal changes, all female volunteers were studied in the luteal phase; that is between days À10 and À3 from the end of their regular menstrual cycle.
Noradrenaline dose-dependently increased SBP and DBP and decreased pulse rate in males and females (Po0.01, ANOVA) with significantly greater effect in men (Po0.05). Total electromechanical systole QS2c was significantly shortened in both groups (Po0.01) without gender differences. Noradrenaline plasma concentration increased to 3630 7 319 ng/l (mean 7 s.e.m) and to 3423 7 296 ng/l in men and women, respectively (Po 0.01).
Tyramine dose-dependently increased SBP and DBP in men and women (Po0.01) without differences between groups. A small decrease in pulse rate was seen, which was not statistically significant from baseline in men, but in women (Po0.01). However, no difference in responsiveness between the groups was detectable. QS2c was shortened by tyramine (Po0.01) without differences between sexes. Tyramine increased noradrenaline plasma levels in men (456 7 170 ng/l, Po0.01) and in women (456 7 92 ng/l, Po0.05).
In order to correct for methodological differences between study days, drug responses during coinfusion of propranolol were compared at approximately equivalent plasma noradrenaline concentrations. Following exogenous noradrenaline, plasma noradrenaline concentrations were 1928 ng/l (95% CI: 1698-2159) and 2216 ng/l (95% CI: 1642-2751) in males, and 2347 ng/l (95% CI: 1898-2796) and 2216 ng/l (95% CI: 995-3438) in females in the absence and presence of propranolol, respectively. Tyramine-increased plasma noradrenaline concentrations were 463 ng/l (95% CI: 81-844) and 503 ng/l (95% CI: 383-622) in males, and 439 ng/l (95% CI: 198-680) and 486 ng/l (95% CI: 397-575) in females in the absence and presence of propranolol, respectively. In the presence of propranolol (Figure 1 ) exogenous noradrenaline caused a comparable effect on mean arterial pressure (MAP) and pulse rate in men. In women, the pressor effect of noradrenaline was slightly more pronounced during beta-blockade, and its effect on pulse rate significantly enhanced (Po0.01). Thus, the differences between men and women to exogenous NA were mitigated during propranolol (Figure 1 ). QS2c was prolonged in both groups to a similar degree between sexes. Co-infusion of propranolol augmented the tyramine-induced changes of MAP in females (Po0.01). Effects on pulse rate were similar between groups, and the tyramine-induced shortening of QS2c was reduced by propranolol in men and women (Po0.05).
These data demonstrate sex differences in the systemic haemodynamic response to noradrenaline infusion, but not to endogenously increased noradrenaline by tyramine. Exogenous noradrenaline caused a significantly smaller pressor response in women than in men, which can be partly explained by a different vascular beta 2 adrenoceptor responsiveness as these gender differences were mitigated during propranolol co-administration. Thus, premenopausal women seem to be protected against noradrenaline-induced vasoconstriction by counterregulatory beta 2 adrenoceptor-induced vasodilation. This corroborates experiments in the forearm vasculature [3] [4] [5] and is in good agreement with our previous results using the alpha adrenoceptor agonist phenylephrine, where no gender differences were seen 8 and the same experiments could also not reveal sex differences to nonspecific beta adrenoceptor stimulation by small doses of isoprenaline.
The smaller pressor response to exogenous noradrenaline in women was seen in the absence of differences in systolic time intervals suggesting that there is no sex difference in the distribution or the sensitivity of cardiac beta 1 adrenoceptors. Again, these results are in accordance with previous studies. 8, 9 These functional experiments also demonstrate that the vascular response caused by elevated luminal concentrations of noradrenaline is different from that released neuronally. 10 An increase in systemic plasma concentrations of noradrenaline by exogenous infusion by approximately nine-fold as compared to tyramine did only translate into a three-fold increased blood pressure response.
Tyramine seems to exert its cardiac effects also through other mechanisms than elevated concentrations of circulating noradrenaline. Our results with tyramine are at variance with Schäfers et al, 11 who reported a reduction in DBP and an increase in SBP and cardiac inotropic performance in healthy males and concluded that the effects of intravenous tyramine are mainly mediated by Figure 1 Effect of intravenous noradrenaline (a) and tyramine (b) given alone or in the presence of propranolol at equivalent noradrenaline plasma concentrations. Percent changes from baseline mean arterial blood pressure, pulse rate and total electromechanical systole QS2c in males (n ¼ 10, hatched columns) and females (n ¼ 9, open columns) are presented as means 7 s.e.m. beta 1 adrenoceptors. These findings could not be reproduced in our study, which may be due to a different study cohort. In our experimental setting, the dose of propranolol was not high enough to antagonize cardiac betaadrenoceptors completely. The decrease in heart rate in women was even greater to tyramine and an even greater shortening of QS2 c was seen to tyramine than to noradrenaline in both sexes in our study. This notion could point towards a gender different mechanism of endogenously released noradrenaline in the heart, with beta-adrenoceptor-mediated preference for chronotropic or inotropic function between males and females.
The influence of the baroreflex feedback system, 12 which is an important regulatory mechanism against rapid changes in arterial pressure, was not controlled for in the present experiments and could have influenced the results. Further, there are no in vitro data currently available on a genderspecific distribution or responsiveness of adrenoreceptors in human blood vessels. Interestingly, beta 2 adrenoceptor gene polymorphisms may play a role in the response to laryngoscopy and tracheal intubation, 13 and determine vascular arterial and venous reactivity.
14 However, this genetic polymorphism does not translate into an altered risk of hypertension. 15 These experiments suggest that premenopausal women may be better protected against sudden increases of circulating catecholamines, which could contribute to the lower incidence of cardiovascular diseases in women.
